Mesenchymal Stem Cells versus Mesenchymal Stem Cells Combined with Cord Blood for Engraftment Failure after Autologous Hematopoietic Stem Cell Transplantation: A Pilot Prospective, Open-Label, Randomized Trial  by Xiong, Yi-Ying et al.
Biol Blood Marrow Transplant 20 (2014) 236e242American Society for Blood
ASBMT
and Marrow TransplantationMesenchymal Stem Cells versus Mesenchymal Stem Cells
Combined with Cord Blood for Engraftment Failure after
Autologous Hematopoietic Stem Cell Transplantation: A
Pilot Prospective, Open-Label, Randomized Trial
Yi-Ying Xiong 1,y, Qian Fan 1,y, Fen Huang 1, Yu Zhang 1, Yu Wang 2,
Xiao-Yong Chen 3, Zhi-Ping Fan 1, Hong-Sheng Zhou 1, Yang Xiao 4,
Xiao-Jun Xu 5, Min Dai 1, Na Xu 1, Jing Sun 1, Peng Xiang 3, Xiao-Jun Huang 2,
Qi-Fa Liu 1,*
1Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
2 Institute of Hematology, Peking University People’s Hospital, Beijing, China
3Center for Stem Cell Biology and Tissue Engineering, Sun Yat-Sen University, Guangzhou, China
4Department of Hematology, General Hospital of Guangzhou Military Command of PLA, Guangzhou, China
5Department of Hematology, Zhongshan People0s Hospital, Sun Yat-Sen University, Zhongshan, ChinaArticle history:
Received 29 August 2013
Accepted 3 November 2013
Key Words:
Engraftment failure
Mesenchymal stem cells
Cord blood
Autologous hematopoietic stem
cell transplantationFinancial disclosure: See Acknowl
This trial is registered at www.Clin
* Correspondence and reprint re
tology, Nanfang Hospital, Southern
China.
E-mail address: liuqifa628@163
y Y.Y.X. and Q.F. contributed equ
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Engraftment failure (EF) after autologous hematopoietic stem cell transplantation is a serious complication.
We prospectively evaluated the effects and safeties of mesenchymal stem cells (MSCs) alone and MSCs
combined with cord blood (CB) for EF. Twenty-two patients were randomized to receive MSCs (MSC group;
n ¼ 11) or MSCs plus CB (CB group; n ¼ 11). Patients with no response (NR) to MSCs received the therapeutic
schedule in the CB group, and those patients with partial response (PR) in the MSC group and patients
without complete remission (CR) in the CB group received another cycle of MSC treatment. Patients who did
not achieve CR after 2 cycles of treatments received other treatments, including allogeneic HSCT. After the
ﬁrst treatment cycle, response was seen in 7 of 11 patients in the MSC group and in 9 of 11 in the CB group
(P ¼ .635), with a signiﬁcant difference in neutrophil reconstruction between the 2 groups (P ¼ .030). After
2 treatment cycles, 16 patients achieved CR, 3 achieved PR, and 3 had NR. No patient experienced graft-
versus-host disease (GVHD). With a median follow-up of 345 d (range, 129 to 784 d) post-transplantation,
18 patients remained alive and 4 had died (3 from primary disease relapse and 1 from cytomegalovirus
pneumonia). The 2-year overall survival, disease-free survival, and cumulative incidence of tumor relapse
post-transplantation were 75.2%  12.0%, 79.5%  9.4%, and 20.5%  9.4%, respectively. Our data indicate that
the 2 strategies are effective for EF and do not result in GVHD or increase the risk of tumor relapse, but the
MSC plus CB regimen has a superior effect on neutrophil reconstruction.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Autologous hematopoietic stem cell transplantation
(auto-HSCT) is considered a standard treatment for many
malignancies, including lymphomas, myelomas, and leuke-
mias [1-4]. Engraftment failure (EF) after auto-HSCT is a
serious complication occurring in 2% to 9.5% of patients,
associatedwith considerablemorbidity andmortality related
to infections and hemorrhagic complications [3-6]. Fortu-
nately, with the wide application of mobilized peripheral
blood stem cells (PBSCs) instead of bone marrow (BM) as a
graft source, this complication is becoming increasingly
uncommon.
Available treatment options for patients with EF are
limited and include hematopoietic growth factors, autologous
stem cell reinfusion, and allogeneic hematopoietic stem cell
transplantation (allo-HSCT) [3,6-10]. Hematopoietic growth
factors have been administered to promote hematopoieticedgments on page 241.
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13.11.002engraftment, but are usually effective only in the short term
and have no effect on platelet (PLT) engraftment [8,10]. Allo-
HSCT is associated with a high risk of graft-versus-host dis-
ease (GVHD) and transplantation-related mortality [3,8]. The
ideal treatment is reinfusion of autologous stem cells, but a
lack of stored cells as a backup is a signiﬁcant obstacle to this
approach [6].
Mesenchymal stem cells (MSCs), a type multipotent adult
stem cell that can be isolated from BM, adipose tissue, and
cord blood (CB), have the capacity for suppressing immu-
nologic responses, supporting hematopoiesis and regulating
the inﬂammatory response [4,11-14]. Clinical applications of
MSCs are evolving rapidly, with the goal of promoting he-
matopoietic engraftment in HSCT [15-18]. Recent studies
have shown that MSCs are effective for poor graft function
(PGF) after allo-HSCT [15,16,19-21]. In our previous practice
(an experimental treatment under the consent of the patient
andwas not public), 1 patient who experienced EF after auto-
HSCT failed to respond to MSCs treatment, but achieved
hematopoietic reconstruction after coinfusion of MSCs and
CB.
Based on these previous studies, we performed a pro-
spective multicenter clinical trial of treatment for EF after
auto-HSCT with ex vivoeexpanded MSCs derived from
HLA-mismatched BM alone and in combination withTransplantation.
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safety of the 2 strategies.PATIENTS AND METHODS
Patients
Patients with EF after auto-HSCT were eligible for the study if they were
age 14 to 60 yr with no abnormal vital signs (ie, heart rate, respiratory rate,
or blood pressure) or the presence of active visceral hemorrhage at the time
of study initiation. The diagnostic criteria for EF after auto-HSCT were based
on the literature [1,6] and included (1) an absolute neutrophil count (ANC)
0.5  109/L and a PLT count 20  109/L for at least 35 consecutive days
post-transplantation, with or without a hemoglobin (Hb) level of 70 g/L;
(2) the presence of hypoplastic/aplastic BM; and (3) the absence of primary
disease relapse.
The study was conducted at Nanfang Hospital of Southern Medical
University, Peking University People’s Hospital, General Hospital of
GuangzhouMilitary Command of PLA, and Zhongshan City People’s Hospital
of Guangdong Province between April 2011 and April 2013.Figure 1. Flow diagram of the study.Trial Design
This was a prospective, multicenter, randomized, open-labeled, parallel-
group study with a minimum recruitment of 20 cases. All patients were
randomized with 1:1 allocation to receive either MSCs alone (MSC group) or
MSCs combined with CB (CB group). The randomization code was generated
by computer for each participating center.
The study was performed in accordance with the tenets of the modi-
ﬁed Helsinki Declaration, and is registered at www.ClinicalTrials.gov
(NCT01763099, Mesenchymal Stem Cells Combined with Cord Blood for
Treatment of Graft Failure). Our protocol was approved by the respective
Ethics Review Boards before study initiation. All recipients and/or guard-
ians, as well as donors, provided written informed consent to participate in
the study.MSC Manufacture and CB Choice
BM-derived MSCs were obtained from HLA-mismatched unrelated do-
nors after written informed consent was obtained. Isolation and ex vivo
expansion of MSCs were done as described previously [14]. In brief,
mononuclear cells were suspended in human MSC growth medium at a
density of 5000 cells/cm2. After 3 d, nonadherent cells were removed when
the medium was replaced. Adherent cells were cultured further and
passaged. Cells were harvested after 4 or 5 passages and administered to
recipients. The antigen expression of MSCswas evaluated by ﬂowcytometry.
The culture-expanded cells expressed CD29, CD44, CD73, CD90, CD105, and
CD166, but not CD11a, CD34, or CD45. The cells could be induced to differ-
entiate into cells of osteogenic, adipogenic, and chondrogenic lineages when
cultured in appropriate induction media [21].
CB units were provided by the Guangdong Cord Blood Bank (Guangzhou
city of Guangdong province, China). Generally, preferred CB units were
matched 4/6 to 6/6 HLA loci with recipients and contained the most cells.Study Treatment and Response Criteria
In the MSC group, MSCs were administered once every 2 wk, and 2
doses of MSCs composed a cycle of treatment. After 1 treatment cycle
(within 28 d), the patients who were not responsive to MSCs received the
therapeutic schedule of the CB group, and those patients with partial
response (PR) continued with another cycle of MSCs treatment. In the CB
group, MSCs were administered as for theMSC group, along with single-unit
CB on the same day as the ﬁrst MSCs dose. Patients who did not achieve a
complete response (CR) after 1 cycle of MSCs and CB coinfusion continued
on a cycle of MSC treatment. Patients who did not achieve CR after 2 cycles
of treatment (within 56 d) received other treatments, including allo-HSCT.
(Figure 1).
During study treatments, granulocyte colony-stimulating factor (G-CSF)
was given at 5 mg/kg/d and continuing to the achievement of an ANC
>0.5  109/L for 3 consecutive days. Red blood cells (RBCs) or PLT were
transfused with an Hb  70 g/L or PLT count 20.0  109/L.
The responses to study treatments were deﬁned as follows. CR was
deﬁned as ANC >1.5  109/L without G-CSF support and PLT >50  109/L
without transfusion support for 3 consecutive days. PR was deﬁned as ANC
>0.5  109/L without G-CSF support and PLT >20  109/L without trans-
fusion support for 3 consecutive days. NR was deﬁned as a failure to meet
the criteria for CR or PR at more than 56 d after study treatments. Effective
response included CR and PR. Complete chimerismwas deﬁned as>95% CB-
derived cells detected in blood; mixed chimerism, as 5% to 95% CB-derived
cells detected. Relapse of primary diseases was deﬁned according to pub-
lished criteria [22-24].CB Chimerism Detection
The CB chimerism status of recipients was analyzed by short tandem
repeat analysis at þ15 d and þ30 d after CB infusion.
Monitoring of Epstein-Barr Virus and Cytomegalovirus DNA in Blood
During study treatments, Epstein-Barr virus (EBV)-DNA and cytomeg-
alovirus (CMV)-DNA in blood were monitored weekly by real-time quanti-
tative PCR, as described previously [25]. When a patient achieved CR, the
monitoring frequency was reduced to biweekly for the next 6 mo.
Evaluation Points and Deﬁnitions
The primary study endpoint was hematopoietic reconstruction.
Neutrophil reconstructionwas deﬁned as the ﬁrst of 3 consecutive days with
ANC >0.5  109/L without G-CSF treatment, PLT reconstruction was deﬁned
as the ﬁrst of 3 consecutive days with PTL >20  109/L without transfusion
support, and hematopoietic reconstruction was deﬁned as both neutrophil
and PLT reconstruction. Blood counts were performed twice weekly until
ANC>0.5109/L and PLT>20109/L, and thenweekly for 12wk thereafter.
BM aspiration and biopsy were performed at 28 d and 56 d after treatments,
respectively. The secondary endpoints were safety, including adverse events
assessed by the Common Terminology Criteria for Adverse Events v3.0 [26],
infections, and relapse of primary diseases.
In this study, if the treatment of MSCs alone kept on effect for EF in 28 d,
MSCs plus CB was administered the next day. Based on our previous study,
we presumed that CB might facilitate the effect of MSCs on BM exhaustion;
thus, we mainly compared the therapeutic effects of the 2 strategies after 1
treatment cycle. No interim analyses were planned.
Statistical Analysis
SPSS 19.0 (IBM, Armonk, NY) was used to process all data. The Student t
test and Fisher exact test were used to assess differences between the MSC
and CB groups. A P value <.05 was considered signiﬁcant. The Kaplan-Meier
method was used to estimate overall survival (OS), disease-free survival
(DFS), and cumulative incidence of primary disease relapse.
RESULTS
Twenty-three of the 381 patients who underwent auto-
HSCT between April 2011 and April 2013 experienced EF.
Twenty-two of these patients with EF met the inclusion
criteria and were enrolled in this trial, with 11 patients in the
MSC group and 11 in the CB group. All patients completed the
ﬁrst treatment cycle (2 doses of MSCs in MSC group, and 2
doses of MSCs and one dose of CB in CB group), and those
Figure 2. Diagram showing the ﬂow of study participants (according to the CONSORT 2010 statement [27]) in the MSC and CB groups.
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completed the planed doses. Figure 2 shows a ﬂow chart of
the estimated number of screened patients and the number
of randomized and analyzed patients according to the
CONSORT 2010 statement [27] for reporting parallel-group
randomized trials.Clinical Characteristics of Patients before Study
Treatments
The median patient age was 40 yr (range, 14 to 55 yr).
Primary diseases included acute myelogenous leukemia
(AML; n ¼ 15), acute lymphoblastic leukemia (ALL; n ¼ 2),
multiple myeloma (MM; n ¼ 4), and non-Hodgkin lym-
phoma (NHL; n ¼ 1). The median number of courses of
chemotherapy before HSCT, including the chemotherapy of
PBSC mobilization and the conditioning regimen, was 9
(range, 7 to 14). One patient with NHL and 1 patient withMM
had PR; 3 patients with leukemia were in complete hema-
tologic remission but not molecular remission, including 1
MLL-positive patient and 2 AML1/ETO-positive patients. The
other patients were in ﬁrst CR (CR1) at the time of trans-
plantation. Remission standards for primary diseases were
according to published criteria [22-24]. Seven patients had
hepatitis B virus infection, 1 patient had a history of ovarian
cancer, and 1 patient had a history of breast cancer before the
onset of primary disease. Four patients with MM experi-
enced EF after a second HSCT, and the other patients expe-
rienced EF after their ﬁrst transplantation.
All patients received the protocol of EA chemotherapy
(etoposide 0.2 g/d and cytarabine 2 g/d on days 1 to 3)
combined with G-CSF 5 mg/kg/d, continuing until completion
of PBSC collection for PBSC mobilization. PBSCs were har-
vested at a WBC count >3.0  109/L. Twenty-one patients
received mobilized PBSC transplants, and 1 patient received
a BM transplant because of mobilization failure. The condi-
tioning regimens included total body irradiation
(TBI)þ cyclophosphamide (CY) (4.5 Gy/day of TBI on days5
and 4; CY 60 mg/kg/d on days 3 and 2) in 5 patients (1
with NHL, 2 with ALL, and 2 with AML), busulfan (BU) þ CY
(BU 4.0mg/kg/d on days7 to4; CY 60mg/kg/d on days3and 2) in 13 patients with AML, and melphalan (MEL) þ CY
(MEL 200 mg/m2/d on day 5; CY 60 mg/kg/d on days 4
and 3) in 4 patients with MM. The median number of
transfused nucleated cells was 6.12  108/kg (range, 3.33 to
8.80  108/kg) and that of CD34þ cells was 4.36  106/kg
(range, 2.72 to 7.55  106/kg). G-CSF was administered at
5 mg/kg/d starting at day þ3 after transplantation and
continued until an ANC >0.5  109/L was achieved for 3
consecutive days. Clinical transplantation characteristics and
patient outcomes are summarized in Table 1.
Patients received sporadic transfusion of PLT and/or RBCs
before study treatments. The median ANC, PLT counts, and
Hb levels at the time of study treatments were 0.15  109/L
(range, 0.01 to 0.44  109/L) and 12.0109/L (range, 6.0 to
19.0109/L), and 69.01012/L (range, 56.0 to 95.0 1012/L),
respectively, in the MSC group and 0.31109/L (range, 0.04 to
0.48109/L), 11.0109/L (range, 4.0 to 19.0109/L), and
71.01012/L (range, 58.0 to 79.01012/L), respectively, in the
CB group. Six patients had a bacterial and/or fungal infection
(bacterial septicemia in 1, bacterial pneumonia in 2, fungal
pneumonia in 2, and mixed bacterial and fungal pneumonia
in 1) at the time of study treatments. One patient exhibited
EBV-DNA viremia and 5 patients had CMV-DNA viremia
before study treatments, but all 6 patients were negative
after treatment with rituximab and foscarnet plus globulin,
respectively, at the time of study treatments. Patient baseline
demographic and clinical characteristics were similar in the
2 groups (Table 1).Treatment and Response
The median interval from HSCT to the onset of study
treatment was 51 d (range, 40 to 64 d) in the MSC group and
53 d (range, 40 to 65 d) in the CB group (P¼ .281). Themedian
number of MSC courses per patient was 4 (2 to 4) in the MSC
group versus 2 (2 to 4) in the CB group (P ¼ .507), and the
median MSC dose was 4.30  106 cells/kg (range, 2.12 to
5.18 106 cells/kg) in theMSC group versus 2.73 106 cells/kg
(range, 2.00 to 5.47  106 cells/kg) in the CB group (P ¼ .390).
Among the 15 recipients of CB, 10 patients received 5/6 HLA-
matched CB and 5 received 4/6 HLA-matched CB. In this
Table 1
Clinical Transplantation Characteristics and Patient Outcomes
Patient Group Sex/Age, yr Disease/Status Courses of Chemotherapy*
(Conditioning Regimen)
Transfused
CD34þ 106 Cells/kg
MSCsy CBz/CD34þ Cellsx
(HLA Match)
Effect Outcome
Cycle 1 Cycle 2
1 MSC F/55 MM/CR 9 (MEL þ CY) 2.13 4.30 5.00/2.21 (5/6) NR PR Survived
2 MSC M/54 MM/CR 13 (MEL þ CY) 1.21 4.40 - PR CR Survived
3 MSC F/39 AML/CR1 7 (BU þ CY) 1.62 2.70 - CR - Survived
4 MSC M/20 ALL/CR1 8 (TBI þ CY) 0.87 4.49 6.00/2.40 (4/6) NR CR Survived
5 MSC F/37 AML/CR1 8 (BU þ CY) 1.02 2.50 - CR - Survived
6 MSC F/19 AML/CR1 8 (BU þ CY) 0.83 2.40 - CR - Survived
7 MSC F/52 AML/CR2k 14 (BU þ CY) 0.72 4.69 5.80/2.74 (5/6) NR NR Died{,#
8 MSC F/54 AML/CR1k 8 (BU þ CY) 1.00 5.14 - PR CR Survived{
9 MSC M/51 AML/CR1 6 (BU þ CY) 0.99 2.60 - CR - Survived
10 MSC F/39 AML/CR1 5 (BU þ CY) 2.30 5.18 6.50/3.01 (5/6) NR PR Survived
11 MSC F/42 AML/CR1 6 (BU þ CY) 1.32 2.12 - CR - Survived
12 CB F/40 AML/CR1** 6 (TBI þ CY) 1.60 5.02 7.20/3.09 (5/6) PR CR Died{,#
13 CB F/34 AML/CR1 9 (TBI þ CY) 1.45 2.36 5.50/1.75 (4/6) CR - Survived
14 CB F/44 AML/CR1 7 (BU þ CY) 2.34 2.26 6.50/2.70 (5/6) CR - Survived
15 CB M/14 AML/CR1 8 (BU þ CY) 2.55 5.47 5.50/1.78 (5/6) PR CR Survived
16 CB F/54 MM/PR 9 (MEL þ CY) 1.24 4.64 6.30/2.43 (4/6) PR PR Survived
17 CB M/40 NHL/PR 7 (TBI þ CY) 1.40 4.47 5.50/2.34 (4/6) NR NR Died{
18 CB F/52 AML/CR1 6 (BU þ CY) 1.89 2.00 6.50/3.03 (5/6) CR - Survived
19 CB F/36 MM/CR 8 (MEL þ CY) 1.20 2.27 6.80/2.89 (5/6) CR - Survived
20 CB F/49 AML/CR1 7 (BU þ CY) 1.66 2.40 6.00/2.01 (5/6) CR - Survived
21 CB M/26 AML/CR1 10 (BU þ CY) 0.84 2.73 6.402.45 (5/6) CR - Survived
22 CB F/40 ALL/CR1 7 (BU þ CY) 1.87. 4.06 5.70/2.38 (5/6) NR CR Diedyy
* Including the chemotherapy of PBSC mobilization and conditioning regimen.
y 106 cells/kg body weight.
z 107 cells/kg body weight.
x 105 cells/kg body weight.
k Patients with no molecular remission (ETOþ).
{ Patients experienced relapse after 2 treatment cycles.
# Patients died of tumor relapse after 2 treatment cycles.
** Patient with no molecular remission (MLLþ).
yy Patient died of CMV pneumonia after allo-HSCT after 2 treatment cycles (AML1/ETOþ).
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kg (range, 5.00 to 7.20  107 cells/kg), and that of CD34þ cells
was 2.43  105 cells/kg (range, 1.75 to 3.12  105 cells/kg)
(Table 1).
After 1 cycle of treatment, in the MSC group, 5 patients
achieved CR, 2 achieved PR, and 4 had NR, and in the CB
group, 6 patients achieved CR, 3 achieved PR, and 2 had NR.
The rate of effective response was similar in the 2 groups
(7 of 11 versus 9 of 11; P¼ .635). The CR and PR rates were not
signiﬁcantly different between the 2 groups (P ¼ 1.000 for
both). Among the 16 patients achieving a response after the
ﬁrst cycle of treatments, the median time to hematopoietic
reconstruction was 21 d (range, 18 to 28 d) in the MSC group
and 18 d (range, 12 to 26 d) in the CB group (P ¼ .046). There
was a statistically signiﬁcant between-group difference in
neutrophil reconstruction, with 18 d (range, 9 to 28 d) in the
MSC group and 8 d (range, 6 to 25 d) in the CB group
(P ¼ .030), but not in PLT reconstruction, with 21 d (range, 18
to 28 d) in the MSC group and 18 d (range, 11 to 26 d) in the
CB group (P ¼ .091) (Table 2).
Eleven patients without CR all entered to the second cycle
of treatments (2 with PR and 4 with NR in the MSC group,
and 3 with PR and 2 with NR in the CB group). In the MSC
group, 1 patient with PR achieved CR and another patient
with PR remained in PR after a second cycle of MSC treat-
ment. Of the 4 patients with NR, 2 achieved CR, 1 achieved
PR, and 1 remained with NR after 1 cycle of MSC plus CB
treatment. In the CB group, 3 patients with PR all achieved
CR, and 2 patients with NR remained with NR after the sec-
ond cycle of treatment. At the time of this report, among the
5 patients without CR (2 with PR and 1 with NR in the MSC
group and 2 with NR in the CB group), after 2 cycles of
treatments, in the MSC group, 1 patient with PR had been inPR for 109 d after treatment, the other patient in PR under-
went allo-HSCT at day þ273 after auto-HSCT because of
primary disease relapse, and the patient with NR died of
tumor relapse at day þ156 post-transplantation, and in
the CB group, 1 patient with NR underwent allo-HSCT at
day þ249 after auto-HSCT because of primary disease
relapse, and the other patient with NR died of tumor relapse
at day þ195 post-transplantation.CB Chimerism
Chimerism analysis of peripheral blood samples identi-
ﬁed no CB genetic markers at 15 d and 30 d after CB
infusion.Infections during Treatment and Follow-Up
In all 6 patients with an infection at the time of study
treatments, the infection under control during the treat-
ments. Four patients developed new episodes of infection
during the study treatments, including 3 with bacterial
infection in the MSC group and 1 with fungal pneumonia in
the CB group. At a median follow-up of 257 d (range, 73 to
297 d) after study treatments, 1 patient in the CB group
developed CMV-DNAviremia at 123 d after study treatments.
No patient in either group developed EBV-DNA viremia or
EBV-associated disease.Toxic Side Effects
No patient experienced any adverse events of grade 3/4
based on CTCAE v3.0, acute GVHD, or chronic GVHD. No
secondary tumors were detected besides primary tumor
relapse.
Table 2
Comparison of the MSC and CB Groups
Variable MSC Group CB Group P
Value
Age, yr, median (range) 42 (19-55) 44 (14-54) NS
Previous courses of
chemotherapy, n, median
(range)
8 (9-14) 9 (7-12) NS
Transfused nucleated  108
cells/kg/, median (range)
6.05 (5.03e8.80) 6.19 (3.33-7.78) NS
Transfused CD34þ  106
cells/kg, median (range)
4.02 (2.72-6.30) 4.60 (2.84-7.55) NS
Interval from auto-HSCT to
study treatment, d, median
(range)
51 (40-64) 53 (40-65) NS
Levels at the time of
treatment
ANC  109/L, median
(range)
0.15 (0.01-0.44) 0.31 (0.04-0.48) NS
PLT  109/L, median (range) 12.0 (6.0-19.0) 11.0 (4.0-19.0) NS
Hb 1012/L, median (range) 69.0 (56.0-95.0) 71.0 (58.0-79.0) NS
MSC doses, n, median (range) 4 (2-4) 2 (2-4) NS
MSCs  106 cells/kg, median
(range)
4.30 (2.12-5.18) 2.73 (2.00-5.47) NS
CB infusion, n 4 11 -
Nucleated cells in CB, 107
cells/kg, median (range)
5.90 (5.00-6.50) 6.30 (5.50-7.20) NS
CD34þ cells in CB,  105
cells/kg, median (range)
2.57 (2.21-3.01) 2.43 (1.75-3.12) NS
Response after 1 cycle of
treatment, n/N
CR 5/11 6/11 NS
PR 2/11 3/11 NS
NR 4/11 2/11 NS
Time to neutrophil
reconstruction, d, median
(range)
18 (9-28) 8 (6-25) 0.030
Time to PLT reconstruction, d,
median (range)
21 (18-28) 18 (11-26) NS
Time to hematopoietic
reconstruction, d, median
(range)
21 (18-28) 18 (12-26) 0.046
NS indicates not signiﬁcant.
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At the time of this report, 18 patients were alive and 4 had
died. The causes of death included tumor relapse in 3 pa-
tients and CMV pneumonia in 1 patient. At a median follow-
up of 345 d (range, 129 to 784 d) post-transplantation, 4
patients experienced relapse of primary disease (at
days þ126, þ130, þ164, and þ273 post-transplantation),
3 patients died of relapse, and 1 patient was alive after
allo-HSCT. One patient died of CMV pneumonia at day þ434Figure 3. Kaplan-Meier curves for OS, DFS (A), and cumulative incidence of recurren
mulative incidence of tumor relapse post-transplantation were 75.2% (95% CI, 63.2%-8after allo-HSCT because of EF. The 4 patients who experi-
enced relapse were considered at high risk for relapse before
auto-HSCT, including 1 patient with NHL with PR, 1 patient
with leukemia who was MLL-positive, and 2 patients who
were AML1/ETO-positive at the time of transplantation. The
2-year OS, DFS, and cumulative incidence of tumor relapse
post-transplantation were 75.2% (95% conﬁdence interval
[CI], 63.2% to 87.2%), 79.5% (95% CI, 70.1 to 88.9%), and 20.5%
(95% CI, 11.1 to 29.9%), respectively (Figure 3).
DISCUSSION
Several recent reports have described treatment of PGF
after allo-HSCT with MSCs [15,16,19-21]. To our knowledge,
the present study is the ﬁrst to use MSCs alone or in com-
bination with CB to treat EF after auto-HSCT. Our results
indicate that both strategies are effective for treating EF. The
time to hematopoietic reconstruction in patients who
received MSCs in combination with CB was superior to that
in patients who received MSCs alone. In addition, 3 of the 4
patients who with NR to treatment with MSCs alone ob-
tained hematopoietic reconstruction after treatment with
MSCs plus CB.
The rate of EF after auto-HSCT in the present study of
6.04% is similar to that reported in the literature [3-6].
Numerous factors may inﬂuence hematopoietic reconstruc-
tion in recipients of auto-HSCT, including disease status
before and after transplantation, intensity of conditioning
regimen, and dose and quality of hematopoietic stem cells
(HSCs) [1,3,10,28-33]. We analyzed various factors inﬂu-
encing hematopoietic reconstruction, including age (50 yr
versus >50 yr), courses of previous chemotherapy (7
versus >7), disease type (leukemia versus lymphoma versus
MM), disease status before transplantation (CR versus no
CR), and number of transfused CD34þ cells/kg (less than or
equal to the median versus greater than themedian; median,
5.5  106 cells/kg). Univariate analysis revealed an associa-
tion between the number of courses of previous chemo-
therapy and the success of hematopoietic reconstruction
(P ¼ .037).
A growing body of experimental and clinical evidence
suggests that MSCs support hematopoiesis via secretion of
hematopoietic cytokines and/or reconstitution of the BM
stroma [1,12,16-18,34]. The coinfusion of HSCs and MSCs
can promote engraftment in both allo-HSCT and auto-HSCT
[15-18]. In addition, we have found that MSCs can promote
engraftment in patients with immune-associated BM
exhaustion through immunoregulation [21,35]. Regardingce (B) in the 22 patients undergoing auto-HSCT. The 2-year OS, DFS, and cu-
7.2%), 79.5% (95% CI, 70.1%-88.9%), and 20.5% (95% CI, 11.1%-29.9%) respectively.
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HSCT recipients, Koc et al. [18] proposed that coinfusion of
autologous PBSCs and MSCs promotes hematopoiesis in
recipients by regenerating the BM microenvironment
damaged by previous chemotherapy or radiotherapy. Given
that EF was related mainly to the number of courses of
chemotherapy before transplantation in our cohort, we
suggest that MSCs promote hematopoietic reconstruction
by their effect on regenerating the BMmicroenvironment. In
addition, because 3 of the 5 patients without CR after 2 cy-
cles of study treatments experienced early relapse post-
transplantation, we proposed that a high residual tumor
burden might affect the therapeutic effects of the 2 strate-
gies for treating EF.
CB is characterized by high HSCs and stromal cell content
[36,37]. Since the ﬁrst CB transplantation performed by
Gluckman et al. [38] in 1988, CB has been offered in many
clinical practices as an alternative source of HSCs, promoting
hematopoietic reconstruction and tissue repair [39-42].
Recently, Li et al. [39] reported that patients with severe
aplastic anemia receiving high-dose CY/ATG combined with
CB infusion as ﬁrst-line therapy achieved rapid and complete
reconstruction of autologous hematopoiesis, and suggested
that CB’s role in supporting hematopoiesis was related to the
stromal cells in CB, which might enhance the ability of the
BM microenvironment to support hematopoiesis. Liu et al.
[43] reported similar results in patients with severe aplastic
anemia undergoing CB transplantation. Our results indicate
that the therapeutic effect of MSCs plus CB is superior to that
of MSCs alone for EF, but did not show CB engraftment in the
blood. Based on these results, we suggest that this superi-
ority is not attributed to CB engraftment. Whether CB and
MSCs act independently or interact together to promote
hematopoietic reconstruction in patients with EF requires
further exploration. One weakness of this study is that we
did not include a CB-only arm because of an insufﬁcient
number of patients.
It is widely believed that MSC infusion does not result in
GVHD. Although CB is characterized by lower immunore-
activity compared with PBSCs or BM [4,38], CB trans-
plantation carries a risk of GVHD. In recipients with BM
exhaustion, the possibility of GVHD due to allogenic CB
infusion is of concern. Our results indicate that the coinfu-
sion of ex vivoeexpanded MSCs derived from HLA-
mismatched BM and CB did not result in GVHD in patients
with EF after auto-HSCT. This might be because MSCs sup-
pressed CB, inducing GVHD, or because CB did not achieve
engraftment in recipients; however, larger samples and
more research are needed. Whether the immunosuppres-
sive properties of MSCs could increase the risk of tumor
relapse has been a subject of debate, with the controversy
based mainly on results in recipients of allo-HSCT
[11,13,18,20,44]. In a previous study [21], we found that
MSC infusion did not increase the risk of tumor relapse in
patients with PGF after allo-HSCT. In this cohort, 4 patients
experienced tumor relapse, and the 2-year cumulative
incidence of tumor relapse post-transplantation was 20.5%
(95% CI, 11.1% to 29.9%). The incidence of tumor relapse was
no higher than that reported in the literature [5,24,45,46].
None of the patients who relapsed achieved CR before un-
dergoing transplantation, which might be the main factor in
the relapse. Another controversy, stemming mainly from
experimental data, concerns infections. In this report, we
focused mainly on opportunistic viral infections, and our
data show that MSC infusion was not associated with anincreased risk of viral infections, in agreement with our
previous report [21].
CONCLUSION
Our data suggest that ex vivoeexpanded MSCs derived
from HLA-mismatched BM alone or combined with unre-
lated CB are effective in treating EF after auto-HSCT, but that
the combination therapy has a superior effect on neutrophil
reconstruction. The 2 strategies do not result in GVHD or
increase the risk of tumor relapse in patients with EF. Taking
into account the limitation of the small number of patients in
our study cohort, our results await conﬁrmation and evalu-
ation in larger series.
ACKNOWLEDGMENTS
Financial disclosure: This project was supported by the
NationalHighTechnologyResearchandDevelopmentProgram
of China (863 Program) (2011AA020105), the National Natural
Science Foundation of China (81270647, 81000231), the Sci-
ence and Technology Planning Project of Guangzhou City,
China (201154300104), the Science and Technology Planning
Project of Guangdong Province, China (2009A03020007), and
theNational PublicHealthGrandResearchFoundationofChina
(201202017).
Conﬂict of interest statement: There are no conﬂicts of in-
terest to report.
REFERENCES
1. Rossi A, Cortelazzo S, Bellavita P, et al. Long-term haematological
reconstitution following BEAM and autologous transplantation of
circulating progenitor cells in non-Hodgkin’s lymphoma. Br J Haematol.
1997;96:620-626.
2. Chen J, Gu LJ, Tang JY, et al. Treatment of advanced malignant solid
tumors in children with autologous hematopoietic stem cell trans-
plantation. Chin J Pediatr. 2004;42:924-927.
3. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med.
2006;354:1813-1826.
4. Devetten M, Armitage JO. Hematopoietic cell transplantation: progress
and obstacles. Ann Oncol. 2007;18:1450-1456.
5. Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison
of addition of autologous bone-marrow transplantation to intensive
chemotherapy for acute myeloid leukaemia in ﬁrst remission: results
of MRC AML 10 trial. Lancet. 1988;351:700-708.
6. Pottinger B, Walker M, Campbell M, et al. The storage and re-infusion of
autologous blood and BM as back-up following failed primary he-
matopoietic stem-cell transplantation: a survey of European practice.
Cytotherapy. 2002;4:127-136.
7. Hornedo J, Sola C, Solano C, et al. The role of granulocyte colony-
stimulating factor (G-CSF) in the posttransplant period. Bone Marrow
Transplant. 2002;29:737-743.
8. Freytes CO, Loberiza FR, Rizzo JD, et al. Myeloablative allogeneic he-
matopoietic stem cell transplantation in patients who experience
relapse after autologous stem cell transplantation for lymphoma: a
report of the International Bone Marrow Transplant Registry. Blood.
2004;104:3797-3803.
9. Baron F, Frere P, Fillet G, Beguin Y. Recombinant human erythropoietin
therapy is very effective after an autologous peripheral blood stem cell
transplant when started soon after engraftment. Clin Cancer Res. 2003;
9:5566-5572.
10. Richard S, Schuster MW. Stem cell transplantation and hematopoietic
growth factors. Curr Hematol Rep. 2002;1:103-109.
11. Bernardo ME, Cometa AM, Locatelli F. Mesenchymal stromal cells: a
novel and effective strategy for facilitating engraftment and acceler-
ating hematopoietic recovery after transplantation? Bone Marrow
Transplant. 2012;47:323-329.
12. Dazzi F, Ramasamy R, Glennie S, et al. The role of mesenchymal stem
cells in haemopoiesis. Blood Rev. 2006;20:161-171.
13. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as
guardians of inﬂammation. Mol Ther. 2012;20:14-20.
14. Weng JY, Du X, Geng SX, et al. Mesenchymal stem cell as salvage
treatment for refractory chronic GVHD. Bone Marrow Transplant. 2010;
45:1732-1740.
15. Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo
expanded mesenchymal stem cells accelerates lymphocyte recovery
and may reduce the risk of graft failure in haploidentical hematopoietic
stem-cell transplantation. Blood. 2007;110:2764-2767.
Y.-Y. Xiong et al. / Biol Blood Marrow Transplant 20 (2014) 236e24224216. Meuleman N, Tondreau T, Ahmad I, et al. Infusion of mesenchymal
stromal cells can aid hematopoietic recovery following allogeneic he-
matopoietic stem cell myeloablative transplant: a pilot study. Stem
Cells Dev. 2009;18:1247-1252.
17. Sanchez-Guijo FM, Lopez-Villar O, Lopez-Anglada L, et al. Allogeneic
mesenchymal stem cell therapy for refractory cytopenias after
hematopoietic stem cell transplantation. Transfusion. 2012;52:
1086-1091.
18. Koc ON, Gerson SL, Cooper BW, et al. Rapid hematopoietic recovery
after coinfusion of autologous-blood stem cells and culture-expanded
marrow mesenchymal stem cells in advanced breast cancer patients
receiving high-dose chemotherapy. J Clin Oncol. 2000;18:307-316.
19. Liu K, Chen Y, Zeng Y, et al. Coinfusion of mesenchymal stromal cells
facilitates platelet recovery without increasing leukemia recurrence in
haploidentical hematopoietic stem cell transplantation: a randomized,
controlled clinical study. Stem Cells Dev. 2011;20:1679-1685.
20. Muller I, Kordowich S, Holzwarth C, et al. Application of multipotent
mesenchymal stromal cells in pediatric patients following allogeneic
stem cell transplantation. Blood Cells Mol Dis. 2008;40:25-32.
21. Liu X, Wu M, Peng Y, et al. Improvement in poor graft function after
allogeneic hematopoietic stem cell transplantation upon administra-
tion of mesenchymal stem cells from third-party donors: a pilot
prospective study. Cell Transplant. 2013; http://dx.doi.org/10.3727/
096368912X661339.
22. Durie BG, Harousseau JL, Miguel JB, et al. International Myeloma
Working Group. International uniform response criteria for multiple
myeloma. Leukemia. 2006;20:1467-1473.
23. Cheson BD, Horning SJ, Coifﬁer B, et al. Report of an international
workshop to standardize response criteria for non-Hodgkin’s lym-
phomas. J Clin Oncol. 1999;17:1244-1253.
24. Liu QF, Fan ZP, Zhang Y, et al. Sequential intensiﬁed conditioning and
tapering of prophylactic immunosuppressants for graft-versus-host
disease in allogeneic hematopoietic stem cell transplantation for re-
fractory leukemia. Biol Blood Marrow Transplant. 2009;15:1376-1385.
25. Liu Q, Xuan L, Liu H, et al. Molecularmonitoring and stepwise preemptive
therapy for Epstein-Barr virus viremia after allogeneic stem cell trans-
plantation. Am J Hematol. 2013;. http://dx.doi.org/10.1002/ajh.23452.
26. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a
comprehensive grading system for the adverse effects of cancer
treatment. Semin Radiat Oncol. 2003;13:176-181.
27. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010
statement: updated guidelines for reporting parallel group randomised
trials. BMJ. 2010;340:698-702.
28. Bolwellb B, Goormastic M, Andresen S, et al. Variables associated with
the platelet count 6 weeks after autologous peripheral blood progen-
itor cell transplantation. Bone Marrow Transplant. 1998;22:547-551.
29. Bernstein SH, Nademanee AP, Vose JM, et al. A multicenter study of
platelet recovery and utilization in patients after myeloablative ther-
apy and hematopoietic stem cell transplantation. Blood. 1998;91:
3509-3517.
30. Wallington-Beddoe CT, Gottlieb DJ, Garvin F, et al. Failure to achieve a
threshold dose of CD34þCD110þ progenitor cells in the graft predicts
delayed platelet engraftment after autologous stem cell trans-
plantation for multiple myeloma. Biol. Blood Marrow Transplant. 2009;
15:1386-1393.31. Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with
successful mobilizing and autografting of peripheral blood progenitor
cells in malignant lymphoma. Blood. 1994;83:3787-3794.
32. Goncalves TL, Benvegnu DM, Bonfanti G. Speciﬁc factors inﬂuence the
success of autologous and allogeneic hematopoietic stem cell trans-
plantation. Oxid Med Cell Longev. 2009;2:82-87.
33. Menendez P, Caballero MD, Prosper F, et al. The composition of leu-
kapheresis products impacts on the hematopoietic recovery after
autologous transplantation independently of the mobilization regimen.
Transfusion. 2002;42:1159-1172.
34. Kemp K, Morse R, Sanders K, et al. Alklating chemotherapeutic agents
cyclophosphamide and melphalan cause functional injury to human
bone marrowederived mesenchymal stem cells. Ann Hematol. 2011;
90:777-789.
35. Xiao Y, Jiang ZJ, Pang Y, et al. Efﬁcacy and safety of mesenchymal stem
cell treatment from related donors for patients with refractory aplastic
anemia. Cytotherapy. 2013;15:760-766.
36. Francese R, Fiorina P. Immunological and regenerative properties of
cord blood stem cells. Clin Immunol. 2010;136:309-322.
37. Gluckman E, Rocha V. Cord blood transplantation: state of the art.
Haematologica. 2009;94:451-454.
38. Gluckman E, Broxmever HA, Auerbach AD, et al. Hematopoietic
reconstitution in a patient with Fanconi’s anemia by means of umbil-
ical cord blood from an HLA-identical sibling. N Engl J Med. 1989;321:
1174-1178.
39. Li Y, Sheng Z, Niu S, et al. Rapid and complete reconstitution of
autologous haemopoiesis after cord blood infusion in treatment-naive
patients with severe aplastic anemia receiving high-dose cyclophos-
phamide/ATG therapy. Eur J Haematol. 2013;90:45-50.
40. Takahashi S, Ooi J, Tomonari A, et al. Comparative single-institute
analysis of cord blood transplantation from unrelated donors with
bone marrow or peripheral blood stem-cell transplants from related
donors in adult patients with hematologic malignancies after mye-
loablative conditioning regimen. Blood. 2007;109:1322-1330.
41. Zhou F, Ge L, Yu Z, et al. Clinical observations on intensive immuno-
suppressive therapy combined with umbilical cord blood support for
the treatment of severe aplastic anemia [letter]. J Hematol Oncol. 2011;
4:27.
42. Robinson SN, Simmons PJ, Yang H, et al. Mesenchymal stem cells in
ex vivo cord blood expansion. Best Pract Res Clin Haematol. 2011;24:
83-92.
43. Liu HL, Sun ZM, Geng LQ, et al. Unrelated cord blood transplantation for
newly diagnosed patients with severe acquired anemia using a
reduced-intensity conditioning: high graft rejection, but good survival.
Bone Marrow Transplant. 2012;47:1186-1190.
44. Ning H, Yang F, Jiang M, et al. The correlation between cotrans-
plantation of mesenchymal stem cells and higher recurrence rate in
hematologic malignancy patients: outcome of a pilot clinical study.
Leukemia. 2008;22:593-599.
45. Sun HY, Li ZY, Xu KL, et al. The clinical study of hematopoietic stem cell
transplantation for hematological malignancies. Leuk Lymphoma. 2006;
15:121-123.
46. Laudi N, Arora M, Burns LJ, et al. Long-term follow-up after autologous
hematopoietic stem cell transplantation for low-grade non-Hodgkin
lymphoma. Biol Blood Marrow Transplant. 2005;11:129-135.
